| Autor: |
Hans Römers, MSc, Vincent van Dijk, PhD, MD, Lucas Boersma, PhD, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Heart Rhythm O2, Vol 4, Iss 1, Pp 59-64 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2666-5018 |
| DOI: |
10.1016/j.hroo.2022.09.021 |
| Popis: |
Implantable cardioverter-defibrillators have become an established therapy for the prevention of sudden cardiac death due to life-threatening ventricular arrhythmias in the last decades. In all those years, the use of transvenous leads has proven to be the most vulnerable part of the system. The development of the completely subcutaneous implantable cardioverter-defibrillator opened a new era of device therapy outside of the vascular system. The next step, enabling extravascular devices with the option of antitachycardia pacing, is just around the corner. This may become an important option for all patients without a bradycardia pacing indication that are in need for antitachycardia pacing because of monomorphic ventricular tachycardia. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
